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Anticancer effects of 6-shogaol via 
the AKT signaling pathway in oral 
squamous cell carcinoma
Objective: Oral squamous cell carcinoma (OSCC) is one of the common 
type of cancer that leads to death; and is becoming a global concern. 
Due to the lack of efficient chemotherapeutic agents for patients with oral 
cancer, the prognosis remains poor. 6-shogaol, a bioactive compound of 
ginger, has a broad spectrum of bioactivities and has been widely used 
to relieve many diseases. However, its effects on human oral cancer have 
not yet been fully evaluated. In our study, we investigated the anticancer 
effects of 6-shogaol on the proliferation, migration, invasion, apoptosis, 
and underlying mechanisms within human OSCC cell lines. Methodology: 
We investigated the effect of 6-shogaol on the growth of OSCC cells by cell 
viability and soft agar colony formation assay. Migration and invasion assays 
were conducted to confirm the effect 6-shogaol on OSCC cell metastasis. 
Apoptosis was detected by flow cytometry and the underlying mechanism 
on the antigrowth effect of 6-shogaol in OSCC cells was assessed using 
western blotting. Results: In our results, 6-shogaol not only suppressed 
proliferation and anchorage-independent cell growth in OSCC cells, but also 
induced apoptosis by regulating the apoptosis-associated factors such as 
p53, Bax, Bcl-2, and cleaved caspase-3. Migration and invasion of OSCC 
cells were inhibited following the regulation of E-cadherin and N-cadherin 
by 6-shogaol. Additionally, 6-shogaol treatment significantly inhibited the 
PI3K/AKT signaling pathway.  Conclusion: Therefore, our results may provide 
critical evidence that 6-shogaol can be a potential new therapeutic candidate 
for oral cancer. 
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Introduction
Cancer within the oral cavity and pharynx is one 
of the most common types worldwide, occurring 
more often in men than women.1 Oral squamous 
cell carcinoma (OSCC) accounts for more than 90% 
of all oral cancers and is caused by various factors, 
including tobacco, alcohol, and heredity.2 Since most 
oral cancers are diagnosed at a late stage, the 5-year 
survival rate for OSCC patients was reported to be 
approximately of 55%.3 Surgical resection is the 
primary treatment for most oral cancers, followed by 
either radiation or chemotherapy, or a combination 
thereof.4 Despite advances in anticancer treatment 
techniques, patients with oral cancer develop esthetic 
and functional impairments due to the surgical defect 
at the head and neck region.5 As a result, the patient’s 
quality of life deteriorates. Therefore, it is important 
to develop nontoxic and effective new drugs for the 
prevention and treatment of oral cancer in patients.
Compared to traditional cytotoxic agents, recent 
oncology has focused on molecules regulating signal 
transduction pathways, which are key factors in cancer 
development. Of these pathways, AKT signaling is 
a central mechanism for carcinogenic activation. 
The AKT-modified expression has been implicated 
in various cancers, including esophageal and colon 
cancer, and is also associated with cell growth, 
apoptosis or epithelial–mesenchymal transition (EMT) 
during the process of carcinogenesis.6,7 EGFRvIII and 
phosphorylated AKT are considered as predictive value 
for patient survival outcome.8 Several studies have 
reported that the phosphatidylinositol 3-kinase (PI3K)/
AKT/mammalian target of rapamycin (mTOR) pathway 
is involved in oral cancer progression and the AKT 
signaling pathway may be an important therapeutic 
target of oral cancer.8-11
6-shogaol is one of the major physiologically 
active compounds in dried ginger and has various 
pharmacological activities, including anti-inflammatory, 
antioxidant, and antitumor.12 In particular, the 
antitumor activity of 6-shogaol is displayed by 
regulating signaling molecules such as AKT, mitogen-
activated protein kinases, signal transducer and 
activator of transcription-3 (STAT3), cyclin D1, Bcl-2 
and caspases; all of these are associated with cell 
proliferation, cell cycle arrest, anti-apoptosis, and 
tumor progression.11,13,14 However, few studies have 
reported on the effect of 6-shogaol in oral cancer.
In our study, we explored the anticancer effects 
of 6-shogaol on cell proliferation and the mechanisms 
involved in regulating survival in human OSCC cells.
Methodology
Reagents and antibodies
6-shogaol (purity ≥ 97% from HPLC and NMR 
analysis) was obtained from Weikeqi Biological 
Technology Co. Ltd (Wuhan, Hubei, China) (Figure 
1A). Dulbecco’s modified Eagle medium (DMEM), 
phosphate-buffered saline (PBS), fetal bovine serum 
(FBS), antibiotic–antimycotic mixture containing 100 
U/ml of penicillin and 100 ug/ml of streptomycin, and 
0.25% trypsin-ethylenediaminetetraacetic acid (EDTA) 
were purchased from Gibco BRL. (Grand Island, NY, 
USA). Anti-p-PI3K, anti-PI3K, anti-p-AKT, anti-AKT, 
anti-p-mTOR, anti-mTOR, anti-Bax, anti-p53, anti-
E-cadherin, and anti-N-cadherin antibodies were 
obtained from Cell Signaling Technology (Danvers, MA, 
USA). Anti-actin, anti-Bax, and anti-Bcl-2 antibodies 
were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA). Dimethyl sulfoxide (DMSO) and 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) were purchased from Sigma-Aldrich 
(St. Louis, MO, USA). 
Cell lines and cell culture
Human OSCC cell lines (YD-10B and Ca9-22) 
were obtained from the Department of Oral Biology, 
College of Dentistry, Yonsei University (Seoul, Korea). 
Human oral mucosal fibroblasts (hOMFs), as a normal 
oral cells, were purchased from Aiyan Biotech Co., 
Ltd (Shanghai, China). OSCC cells and hOMFs were 
cultured in DMEM supplemented with 10% FBS and 
1% antibiotic–antimycotic mixture, and incubated in 
a humidified atmosphere with 5% CO2 at 37°C.
Cell viability assay
Cells (1×104 cells/well) were seeded in 96-well 
plates and cultured in a complete medium overnight. 
The attached cells were incubated in serum-free media 
with varying concentrations of 6-shogaol for 24, 48, 
and 72 h. MTT solution (5 mg/ml) was added to each 
well, and incubated at 37°C for 4 h. The medium was 
subsequently discarded, and DMSO was added to each 
well to dissolve the formazan crystals. The absorbance 
was measured at 570 nm using a microplate reader 
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(Thermo Fisher Scientific, Waltham, MA, USA).
Colony formation assay
OSCC cells (8×103 cells/well), suspended in a 
complete medium, were added to 0.3% agar with 
6-shogaol in the top layer over a base layer of 0.6% 
agar with 6-shogaol. The cultures were maintained 
under 5% CO2 at 37°C for two weeks, as previously 
described.15 Colonies were subsequently visualized 
under a microscope and counted using Image-Pro 
Plus software.
Cell migration and invasion assay
Transwell chambers (Corning Costar, Lowell, MA, 
USA) with 8.0 μm pore polycarbonate membrane 
insert were used for the migration and invasion 
assay according to the manufacturer’s procedure 
and published methods.16 OSCC cells (1×105 cells/
well) were seeded onto the upper surface of 1 mg/ml 
Matrigel-coated membranes (for invasion assay) or 
uncoated membranes (for migration assay), and the 
medium containing 6-shogaol was added to the upper 
and lower chambers. The non-invaded/migrated cells 
from the upper surface were removed after 24 h of 
incubation at 37°C. The invaded/migrated cells on the 
lower surface were fixed with cold 4% formaldehyde, 
permeabilized with 100% methanol, and stained with 
0.5% crystal violet. The membrane with migrated or 
invaded cells was imaged using a Leica SP2 confocal 
microscope (Leica Microsystems, Wetzlar, Germany) 
and quantified using the Image-Pro Plus software.
TUNEL assay
Apoptotic cell death was conducted using the 
terminal deoxynucleotidyl transferase dUTP nick-end 
labeling (TUNEL) assay. OSCC cells (1×105 cells/
well) were seeded on chamber slides and incubated 
in DMEM with 6-shogaol for 24 h. Apoptotic cells 
were detected with the TUNEL assay using the in 
situ apoptosis detection kit (Takara, Shiga, Japan) 
according to the manufacturer’s instructions. Cells 
were stained with DAPI, mounted, and examined using 
fluorescence microscopy (Leica Microsystems). The 
percentage of apoptotic cells were estimated using 
annexin V/propidium iodide (PI) staining as described 
previously.17
Binding assay
Cell lysates were incubated with 6-shogaol-
Sepharose 4B beads (Sepharose 4B only beads served 
as a negative control) in a lysis buffer containing 50 
mM Tris–HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 1 
mM dithiothreitol, 0.01% NP-40, and 2 mg/ml bovine 
serum albumin at 4°C rotator overnight. The beads 
were washed three times with a washing buffer 
containing 50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 
5 mM EDTA, 1 mM dithiothreitol, and 0.01% NP-40. 
The binding was visualized by western blot analysis 
Figure 1- Effects of 6-shogaol on the growth of OSCC cells. (A) The chemical structure of 6-shogaol. (B) The toxicity effect of 6-shogaol 
on human oral mucosal fibroblasts at different concentrations. (C) The morphological analysis of YD-10B and Ca9-22 after treatment 
with 6-Shogaol (100×). (D) The viability of YD-10B and Ca9.22 cells treated with various concentrations of 6-shogaol for 24 h using MTT 
assay. (E) In colony formation assay, representative photographs and quantitative graphs of colonies formed on soft agar from YD-10B 
and Ca9-22 cells treated with 0, 2, 4, and 8 μM 6-shogaol. Data are expressed as the mean ± SEM. * p<0.05, ** p<0.01, and *** p<0.001 
versus control (0 µM 6-shogaol)
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with an anti-AKT antibody.
Western blot analysis
OSCC cells were lysed using a lysis buffer (50 
mM Tris–HCl, 150 mM NaCl, 1% NP-40, 1 mM PMSF, 
protease/phosphatase inhibitor cocktail) for the 
collection of total protein. The protein concentrations 
of samples were quantified using the bicinchoninic 
acid protein assay kit (Thermo Fisher Scientific). 
Equal amounts of protein were loaded onto a sodium 
dodecyl sulfate-polyacrylamide gel, electrophoresed, 
and transferred to a polyvinylidene fluoride membrane 
(Millipore, Billerica, MA, USA). Membranes were 
blocked with 5% nonfat dry milk in Tris-buffered 
saline with 0.1% Tween 20 (TBST) and subsequently 
incubated with primary antibodies overnight at 4°C. 
After washing with TBST, the membranes were 
incubated with HRP-conjugated secondary antibodies 
for 1 h at room temperature. The detected proteins 
were visualized using the Amersham enhanced 
chemiluminescence reagent (GE Healthcare, Little 
Chalfont, UK) and analyzed using Da Vinci software.
Statistical analysis
All quantitative results are expressed as the mean 
± standard error of three independent experiments. 
Significant differences were compared using a two-
tailed independent sample t-test between the different 
groups, and p-values less than 0.05 were considered 
statistically significant.
Results
6-shogaol inhibits the growth of OSCC cells
To investigate the effect of 6-shogaol on the 
growth of oral cancer cells, we conducted assays on 
cell proliferation and colony formation. To first confirm 
the toxicity of 6-shogaol in normal human oral cells, 
we measured the viability of hOMFs by treating with 
different concentrations of 6-shogaol. Figure 1B shows 
that no toxicity was exhibited in normal oral cells 
at 0-10 μM 6-shogaol. According to the previously 
indicated 6-shogaol concentrations, the MTT assay 
determined the viability of OSCC cells. Figures 1C and 
1D show that 6-shogaol dose-dependently suppressed 
the proliferation of both YD-10B and Ca9-22 cells. 
A 20 μM concentration of 6-Shogaol inhibited both 
types of cells by more than 70%. In subsequent 
experiments, we used the concentration of 6-shogaol 
with a survival rate of 80% or more. For anchorage-
independent cell growth assessment, we conducted 
the colony formation assay for two weeks; 6-shogaol 
dose-dependently decreased both the size and the 
number of colonies in the two cell lines (Figure 1E).
6-shogaol suppresses the migration and 
invasion in OSCC cells
To confirm the effects of 6-shogaol on oral cancer 
cell metastasis, we investigated the migration and 
invasive abilities of OSCC cells and the expression 
EMT-related proteins, which play an essential role 
in local recurrence and lymph node metastasis of 
cancer. The results indicated that the ability of OSCC 
cells to migrate and invade was dose-dependently 
reduced by 6-shogaol as compared to the control (0 
μM of 6-shogaol) (Figure 2A). Quantitative analysis 
showed that the migration and invasion were reduced 
by approximately 60%, using 8 μM concentration of 
6-shogaol in both OSCC cell lines. Treatment with 
6-shogaol dose-dependently induced an increase 
in E-cadherin and a decrease in N-cadherin. These 
results inhibited the migration and invasion of OSCC 
cells (Figure 2B). Thus, 6-shogaol may suppress the 
EMT process of human OSCC cells.
6-shogaol induces the apoptosis in OSCC cells
To investigate whether apoptosis affected the 
antigrowth effect of 6-shogaol, we conducted Annexin 
V/PI detection and TUNEL assay in two OSCC cell lines. 
6-shogaol-treated OSCC cells were double-stained 
with annexin V-FITC and PI, and analyzed using a 
flow cytometry. 6-shogaol remarkably induced both 
early and late stages of apoptosis in OSCC cells in 
a dose-dependent manner compared to the control 
(Figure 3A–B). The apoptotic populations treated by 
concentrations of 2, 4, and 8 µM of 6-shogaol were 
measured to be approximately 10%, 20%, and 30% 
in both YD-10B and Ca9-22 cells. From the results 
of the TUNEL assay, it was clear that treatment with 
6-shogaol dose-dependently raised the apoptosis rate 
of OSCC cells compared to the control group (Figure 
3C). To confirm the mechanism of apoptosis which 
was induced by 6-shogaol, the level of apoptosis-
related proteins was also investigated using western 
blotting. 6-shogaol treatment significantly increased 
the expression of p53, Bax, and cleaved caspase-3 in 
a dose-dependent manner, but decreased the anti-
apoptotic protein Bcl-2 (Figure 3C). These results 
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Figure 2- Effects of 6-shogaol on the migration and invasion of OSCC cells. (A) Representative photographs and quantitative graphs of 
the migrated and invaded YD-10B and Ca9-22 cells treated with 0, 2, 4, and 8 μM 6-shogaol using transwell. Data are expressed as the 
mean ± SEM. * p<0.05, ** p<0.01, and *** p<0.001 vs control (0 µM 6-shogaol). (B) Western blot analysis of E-cadherin and N-cadherin 
expression by 6-shogaol treatment in YD-10B and Ca9-22 cells
Figure 3- Effects of 6-shogaol on the apoptosis of OSCC cells. (A and B) Annexin V staining and quantification of apoptosis rates in YD-
10B and Ca9-22 cells by 6-shogaol treatment. Data are expressed as the mean ± SEM. * p<0.05, ** p<0.01, and *** p<0.001 vs control 
(0 µM 6-shogaol). (C) The apoptosis phenomenon of YD-10B and Ca9-22 cells treated with 6-shogaol using the TUNEL assay. (D) The 
expression of cell apoptosis markers, including p53, Bax, Bcl-2, and cleaved caspase-3 in 6-shogaol-treated OSCC cells by western 
blotting
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suggest that 6-shogaol significantly induces the 
apoptosis of OSCC cells.
6-shogaol blocks the PI3K/AKT signaling 
pathway in OSCC cells
To elucidate the regulatory mechanism underlying 
the antigrowth effect of 6-shogaol in OSCC cells, we 
assessed the expression of critical PI3K/AKT pathway 
proteins. We conducted an ex vivo pull-down assay 
with OSCC cell lysates to establish whether AKT is a 
target of 6-shogaol. We identified that 6-shogaol did 
indeed bind with AKT directly (Figure 4A). Significant 
proteins involved in the PI3K/AKT/mTOR signaling 
pathway were subsequently analyzed using western 
blotting. Figure 4B shows that 6-shogaol significantly 
decreased the expression of p-PI3K, p-AKT, and 
p-mTOR in a dose-dependent manner in both YD-10B 
and Ca9-22 cells. However, no significant change in 
the total protein expression of PI3K, AKT, and mTOR 
was observed. Additionally, glycogen synthase kinase 
3beta (GSK3β) was also inhibited following 6-shogaol 
treatment. These results indicate that 6-shogaol may 
increase apoptosis of OSCC cells through the PI3K/
AKT/mTOR signaling pathway.
Discussion
Oral cancer is a common fatal cancer and remains 
a major threat to global public health. Local recurrence 
and lymph node metastasis are considered the mainly 
responsible for the low survival rate in patients with 
OSCC.18,19 Therefore, although current therapeutic 
methods, such as surgical resection and radiotherapy, 
Figure 4- Effects of 6-shogaol on the PI3K/AKT signaling pathway in OSCC cells. (A) Pull-down assay showing 6-shogaol bound to 
AKT. (B) Western blot analysis of the expressions of proteins related to the PI3K/AKT/mTOR signaling pathway in OSCC cells treated by 
6-shogaol
Figure 5- A proposed schematic diagram illustrating the roles of 
AKT signaling pathway by 6-shogaol in OSCC cells. 6-shogaol 
exerts the anticancer effects by regulating cell proliferation, cell 
cycle arrest, and apoptosis via PI3K/AKT signaling pathway by 
targeting AKT
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are necessary, it is difficult to obtain satisfactory 
results because of local recurrence and metastasis 
of cervical lymph nodes after surgery.20 Furthermore, 
despite the advances in drugs for various cancers, 
adjuvant chemotherapy for oral cancer patients has 
not yet been established.21 Recently, compounds 
isolated from plants or fruits have garnered interest 
due to their comparatively lower toxic effects and 
multiple targets.22 Therefore, many researchers are 
investigating natural products to develop effective 
prevention and therapeutic agents for various cancers. 
However, there are few studies on the efficacy of 
natural products for oral cancer. Here, we introduced 
6-shogaol, one of the main compounds in dried ginger, 
which was reported to possess activities in cancer 
prevention.13,23,24 The anticancer ability of 6-shogaol 
has been studied in various cancers;24-26 however, the 
mechanism of 6-shogaol in oral cancer has not yet 
been reported.
Previous reports showed that 6-shogaol plays a 
crucial role in kidney cancer osteoclastogenic activity 
and metastatic potential by suppressing 2-Amino-
1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP).27 
Bawadood et al. reported that 6-shogaol induces 
apoptosis by targeting notch signaling pathway, which 
therefore suppresses breast cancer cells proliferation 
and autophagy.28 It has been shown that targeting 
the TLR4 signaling pathway with 6-shogaol plays an 
important role in cancer therapy.29 Back to our concern, 
our findings suggest that 6-shogaol may affect oral 
cancer cell growth by inhibiting AKT pathway. Notably, 
6-shogaol is a multi-targeted drug.
Our study showed that 6-shogaol inhibits cell 
proliferation by inducing apoptotic cell death in two 
different human OSCC cell lines, YD-10B and Ca9-22. 
The regulation of apoptotic gene expression, such as 
the increase in p53, cleaved caspase-3, and Bax along 
with the decrease in Bcl-2, supports the antitumor 
effect of 6-shogaol on OSCC cells. Moreover, the 
EMT event is a pivotal process in tumorigenesis and 
metastasis.30,31 To further understand EMT mechanisms 
in OSCC cells, we conducted a migration and invasion 
assay using transwell with and without Matrigel in YD-
10B and Ca9-22 cells and confirmed the expression 
of EMT-related proteins. In the two OSCC cell lines, 
6-shogaol treatment significantly suppressed the 
ability of migration and invasion of the cells; resulting 
in an alteration in the expression of EMT markers, 
including promotion of E-cadherin expression and 
inhibition of N-cadherin expression compared to the 
control group. These results indicate the inhibitory 
effect of 6-shogaol on the EMT process in oral cancer 
and also suggest a potential therapeutic value of 
6-shogaol for treating oral cancer.
The mechanism of action assays for 6-shogaol 
in various cancer cells showed that it is involved 
in multiple signaling pathways during initiation, 
progression, and metastasis.26-29,32 As one of the 
important pathways in tumorigenesis, once the PI3K/
AKT/mTOR signaling pathway is activated, various 
oncogenes that can lead to cancer progression are 
upregulated.33 Yang and Wang investigated the role of 
AKT in oral cancer using different compounds.9,34 Kim, 
et al.11 (2014) reported that 6-shogaol could inhibit cell 
proliferation in lung cancer by directly targeting AKT. 
Studies have also reported that 6-shogaol reduces the 
survival of fibrosarcoma cells by inducing an increase 
in ROS production and activation of AKT/mTOR.35 
Furthermore, Matsuo, et al.36 (2018) reported the 
pathologic significance of AKT, mTOR, and GSK3β 
proteins in OSCC patients, and confirmed that GSK3β 
drove the cervical lymph node metastatic spread of 
OSCC cells. Therefore, AKT, mTOR and GSK3β at the 
process of carcinogenesis were appreciated as target 
molecules for the prevention and treatment of oral 
cancer.37
In our study, we confirmed that 6-shogaol could 
directly bind with AKT in oral cancer cells and inhibit 
the downstream effect of AKT. 6-shogaol significantly 
reduced the expressions of p-PI3K, p-AKT, and p-mTOR 
in OSCC cells; and also inhibited GSK3β downstream of 
AKT, which plays an important role in the proliferation 
and apoptosis of cancer cells. As in the aforementioned 
anticancer studies of 6-shogaol in various cancer cells, 
in our study, 6-shogaol also inhibited the PI3K/AKT 
pathway, thus inhibiting cell proliferation and inducing 
apoptosis (Figure 5). Undoubtedly, targeting AKT 
with 6-shogaol will help treat oral cancer. Therefore, 
AKT could be a novel biomarker for diagnosis and 
prognosis and could serve as a therapeutic target for 
patients with oral cancer. Taken together, 6-shogaol 
inhibited cell proliferation, migration, and invasion as 
well as promoted the apoptosis of OSCC cells. These 
results indicate that 6-shogaol may be a potential new 
therapeutic agent for patients with oral cancer.
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Conclusion
Our study shows that 6-shogaol suppresses the 
proliferation of two OSCC cell lines, YD-10B and Ca9-
22, in a dose-dependent manner by targeting AKT. 
The results also indicate that 6-shogaol inhibits the 
EMT process and triggered apoptosis by activating the 
PI3K/AKT/mTOR pathway in OSCC cells. Our findings 
support the development of natural product-derived 
compound as a new therapeutic candidate for patients 
with oral cancer. However, since these are cellular-level 
results, in vivo studies should be further evaluated for 
the potential application of 6-shogaol in the prevention 
and treatment of oral cancer.
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